Samstag, 19.09.2026, Calendar Week 38, 262. day of the year, 103 days remaining until EoY.

Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.

Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

CA67059R1091

Filter zurücksetzen

Do you already know our new terminal view? Click here.

FIGI: BBG002CV5Z46

NRX

NurExone Biologic Inc.

GICS: - · SECTOR: EQTY · SUB-SECTOR: -

NAME

NurExone Biologic Inc.

ISIN

CA67059R1091

TICKER

NRX

MIC

XTSX

REUTERS

NRX.V

BLOOMBERG

NRX CN

Fr., 18.09.2026 NurExone

Newsfeed

NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update | NurExone Biologic Inc.

NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update | NurExone Biologic Inc.

NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications | NurExone Biologic Inc.

NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results | NurExone Biologic Inc.

NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference | NurExone Biologic Inc.

NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy | NurExone Biologic Inc.

NurExone Announces Closing of C$1,066,078 Private Placement | NurExone Biologic Inc.

NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model | NurExone Biologic Inc.

NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership | NurExone Biologic Inc.

Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors | NurExone Biologic Inc.

NurExone Announces Closing of Non-Brokered Private Placement | NurExone Biologic Inc.

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico | NurExone Biologic Inc.

NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update | NurExone Biologic Inc.

NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology | NurExone Biologic Inc.

NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update | NurExone Biologic Inc.

NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization | NurExone Biologic Inc.

NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy | NurExone Biologic Inc.

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update | NurExone Biologic Inc.

NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production | NurExone Biologic Inc.

NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise | NurExone Biologic Inc.

NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis | NurExone Biologic Inc.

NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways | NurExone Biologic Inc.

NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update | NurExone Biologic Inc.

NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana | NurExone Biologic Inc.

NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing | NurExone Biologic Inc.

NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness | NurExone Biologic Inc.

NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results | NurExone Biologic Inc.

NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment | NurExone Biologic Inc.

NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard | NurExone Biologic Inc.

NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups | NurExone Biologic Inc.

New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model | NurExone Biologic Inc.

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update | NurExone Biologic Inc.

NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association | NurExone Biologic Inc.

NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update | NurExone Biologic Inc.

NurExone Expands European Engagement with Investor Events in Germany and Switzerland | NurExone Biologic Inc.

NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025 | NurExone Biologic Inc.

NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update | NurExone Biologic Inc.

NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement | NurExone Biologic Inc.

ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery | NurExone Biologic Inc.

NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation | NurExone Biologic Inc.

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director | NurExone Biologic Inc.

NurExone Biologic Secures Master Cell Bank | NurExone Biologic Inc.

NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage | NurExone Biologic Inc.

NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update | NurExone Biologic Inc.

NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets | NurExone Biologic Inc.

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update | NurExone Biologic Inc.

NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA | NurExone Biologic Inc.

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study | NurExone Biologic Inc.

NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update | NurExone Biologic Inc.

NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences | NurExone Biologic Inc.